{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.387","meta":{"versionId":"4","lastUpdated":"2017-11-29T01:00:05.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.387","version":"20171129","name":"Adjuvant Hormonal Therapy Prostate","status":"active","date":"2017-11-29T01:00:05-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","concept":[{"code":"4164F","display":"Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"}]}]},"expansion":{"identifier":"urn:uuid:cd726a13-6e12-4f15-83b5-a4fbf2afded8","timestamp":"2022-06-10T04:17:54-04:00","total":1,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4164F","display":"Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"}]}}